Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Jie Zhang, Yuqi Gao, Zipeng Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16099-16127
Closed Access | Times Cited: 22

Showing 22 citing articles:

Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies
Wei Zeng, Chi Han, Sarah Mohammed, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 3, pp. 788-808
Closed Access | Times Cited: 21
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 17
Seven-membered N-heterocycles as approved drugs and promising leads in medicinal chemistry as well as the metal-free domino access to their scaffolds
Aleksandra Leśniewska, Piotr Przybylski
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116556-116556
Open Access | Times Cited: 11
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases
Hossein Mousavi, Mehdi Rimaz, Behzad Zeynizadeh
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 9, pp. 1828-1881
Closed Access | Times Cited: 9
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Yijun Xie, Di Xiao, Duo Li, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Recent advances in EZH2-based dual inhibitors in the treatment of cancers
Xiaojuan Yang, Xu Lu, Yang Li
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115461-115461
Closed Access | Times Cited: 13
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses
Xiaoyu Wang, Jie Zhou, Bailing Xu
Bioorganic Chemistry (2025), pp. 108471-108471
Closed Access
Therapeutic Potential of Tricyclic Pyridazinone-Based Molecules: An Overview
Battistina Asproni, Gérard A. Pinna, Paola Corona, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3806-3806
Open Access
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy
Xinxin Li, Cheng Wang, Shang Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116054-116054
Closed Access | Times Cited: 8
Biological Profile of Synthetic and Natural Indole Derivatives: Paving New Paths in Cancer Treatment
Ana Margarida Janeiro, Carolina S. Marques
Drugs and Drug Candidates (2024) Vol. 3, Iss. 3, pp. 488-511
Open Access | Times Cited: 3
Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA
Cheng Wang, Heng Luo, Xinye Chen, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106683-106683
Closed Access | Times Cited: 7
Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship
Amandeep Thakur, Mandeep Rana, Ritika Ritika, et al.
Bioorganic Chemistry (2023) Vol. 141, pp. 106893-106893
Closed Access | Times Cited: 7
Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells
Leyuan Chen, Zhonghao Ren, Yunze Zhang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 2
Targeting selective inhibitors of PARPs in drug discovery and development
Maolin Duan, Jing Gao, Jiajin Li, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 10, pp. 1734-1756
Closed Access | Times Cited: 2
An update on small molecule compounds targeting synthetic lethality for cancer therapy
Jiaxiang Luo, Yang Li, Yiwen Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 278, pp. 116804-116804
Closed Access | Times Cited: 2
Indirubin derivatives as bifunctional molecules inducing DNA damage and targeting PARP for the treatment of cancer
Siyuan Wan, Xinye Chen, Fucheng Yin, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115843-115843
Closed Access | Times Cited: 6
Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer
Sachin Sharma, Kavya Chandra, A. Naik, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
Achieving theranostic probes targeting BRD3/BRD4 for imaging and therapy of tumor
Yuqi Gao, Qiao Liu, Cong Song, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117151-117151
Closed Access | Times Cited: 1
Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies
Mandeep Rana, Amandeep Thakur, Charanjit Kaur, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 10, pp. 1169-1193
Closed Access | Times Cited: 2
Targeting Inhibition of Prognosis-Related Nicotinamide Metabolism Genes, Including Poly (Adp-Ribose) Polymerase 9 (Parp-9) Attenuates Glioma Progression
Dekang Nie, Wei Zeng, Jun Wang, et al.
(2024)
Open Access
Cell Toxicity of Kadsuric Acid from Kadsura coccinea in Human Pancreatic Cancer Cells Through Caspase/PARP Pathway: In Vitro and In Silico Approach
Tấn Khanh Nguyễn, Manh Hung Tran, Truong Tan Trung, et al.
Revista Brasileira de Farmacognosia (2024)
Closed Access
Page 1

Scroll to top